Skip to main content

Month: August 2020

Lithium Americas Reports Second Quarter 2020 Results

VANCOUVER, British Columbia, Aug. 14, 2020 (GLOBE NEWSWIRE) — Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) has reported financial and operating results for the second quarter ended June 30, 2020.This news release should be read in conjunction with Lithium Americas’ unaudited condensed consolidated interim financial statements and management’s discussion and analysis (“MD&A”) for the six months ended June 30, 2020, which are available on the Company’s website and SEDAR.  All amounts are in U.S. dollars unless otherwise indicated.“We remain focused on protecting our workers and communities, while coordinating closely with the Province of Jujuy to ensure we operate responsibly and safely as we begin to restart construction activities over the next few weeks,”...

Continue reading

IH 140647 – Boð á fund skuldabréfaeiganda

IH 140647 – Boð á fund skuldabréfaeigandaFundarboð14. ágúst 2020Með vísan til ákvæða skuldabréfsins IH 140647 („skuldabréfið“) boða Íslandshótel ( „útgefandi“) til fundar eigenda skuldabréfsins sem haldinn verður klukkan 13:00 þann 28. ágúst 2020 í fundarherberginu Útgarði á Hótel Grand, Sigtúni 28, 105 Reykjavík.Dagskrá fundarins:Tillaga í tveimur liðum um breytingu á skilmálum skuldabréfsins, þ.e.:Breytingar á greiðsluferli skuldabréfsins og gjalddögum vaxta og afborgana; ogBreytingar á skilmálum skuldabréfanna um sérstök skilyrði, nánar tiltekið um fjárhagslega skilmála.Meðfylgjandi fundarboði þessu er tillaga útgefanda sem tekin verður fyrir sem og umboðseyðublað.Skráning fundargesta og afhending fundargagna verður á fundarstað frá klukkan 12:30 á fundardegi. Þeim fundargestum sem þess óska verður boðið upp á að taka þátt í fundinum...

Continue reading

SCWorx Announces appointment of Timothy Hannibal, Seasoned Technology Executive and Entrepreneur, as President, Chief Operating Officer and Director

NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) — August 14, 2020, SCWorx Corp. (Nasdaq: WORX) announced today the appointment of Timothy Hannibal as President, Chief Operating Officer and Director.  Mr. Hannibal, currently the Company’s Chief Revenue Officer and Interim CFO, will report to the Board of Directors and be responsible for overseeing the day to day operations of the Company, including financial operations.Mr. Hannibal is a seasoned technology executive and entrepreneur, with nearly 30 years’ experience in SaaS and cloud technology, driving revenue, go-to-market strategies, business development and mergers and acquisitions. Mr. Hannibal joined the Company in January 2019 and has since served as its Chief Revenue Officer and Interim CFO. Prior to joining the Company, Mr. Hannibal was an executive at Primrose Solutions (the predecessor...

Continue reading

RioCan Real Estate Investment Trust Announces August 2020 Distribution

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan”) (TSX: REI.UN) today announced a distribution of 12 cents per unit for the month of August. The distribution will be payable on September 8, 2020 to unitholders of record as at August 31, 2020.About RioCanRioCan is one of Canada’s largest real estate investment trusts. RioCan owns, manages and develops retail-focused, increasingly mixed-use properties located in prime, high-density transit-oriented areas where Canadians want to shop, live and work. As at June 30, 2020, our portfolio is comprised of 221 properties with an aggregate net leasable area of approximately 38.6 million square feet (at RioCan’s interest) including office, residential rental and 15 development properties. To learn more about us, please visit www.riocan.com.Information...

Continue reading

Bio-Path Holdings Reports Second Quarter 2020 Financial Results

HOUSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2020 and provided an update on recent corporate developments.“Despite the challenges from the COVID-19 pandemic, we were able to continue to make significant progress across our clinical development pipeline. Most importantly, as recently announced, we dosed the first patient in Stage 2 of our Phase 2 trial of prexigebersen as a combination treatment for patients suffering with acute myeloid leukemia (AML),” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We believe that this...

Continue reading

Microbix Reports Results for Q3 Fiscal 2020

MISSISSAUGA, Ontario, Aug. 14, 2020 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, reports results for its third quarter and year to date fiscal 2020 (Q3 and YTD) ended June 30, 2020, with an increase of 141% in sales of Quality Assessment products (QAPs™).Management DiscussionOverall, Q3 revenues were down from Q3 2019, due in part to negative pressure on antigen demand for non-COVID infectious disease testing. Specifically, lower antigen revenues were achieved from Europe and Asia, from a combination of pandemic-related patient-flow disruption impacting end-user demand, an unforeseen production issue, order periodicity, and contract pricing adjustments. While antigen sales are now being negatively impacted by the pandemic, they are expected to recover across...

Continue reading

Imara Reports Second Quarter 2020 Financial Results and Business Highlights

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trialReported Phase 2a interim safety and efficacy data at the European Hematology Association Annual Congress and promising clinical outcomes in an Open Label Extension Study that tests IMR-687 for longer durationIMR-687 granted Orphan Drug, Fast Track and Rare Pediatric designationsby the FDA for beta-thalassemiaCompany to host conference call and live webcast today at 8:30 a.m. ETBOSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the second...

Continue reading

LPL Financial Managing Director and Divisional President Andy Kalbaugh to Retire, Effective March 2021

CHARLOTTE, N.C., Aug. 14, 2020 (GLOBE NEWSWIRE) — LPL Financial LLC (Nasdaq:LPLA), a leading retail investment advisory firm, independent broker-dealer and registered investment advisor (RIA) custodian, today announced that Andy Kalbaugh, managing director and divisional president, National Sales and Consulting, will retire at the end of the first quarter of 2021. The firm will conduct an external search to identify a new senior leader to join its management team. “We’ve been fortunate to have Andy as a leader at LPL for more than a decade, during which time he has created immeasurable value for our firm, for our advisors’ practices, and for the financial institutions we support,” said Dan Arnold, president and CEO, LPL Financial. “We’ll use the next several months to conduct a thoughtful search for a new senior leader, and Andy...

Continue reading

Personas Social Announces Filing of Year End Financial Statements

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Personas Social Incorporated (TSX.V: PRSN) (OTCQB: PKSLF) (the “Company”) announces that the audited consolidated financial statements (“Financial Statements”) and Management’s Discussion and Analysis (“MD&A”) for the year ended February 29, 2020 (“FY2020”), are now available on the Company’s profile on SEDAR (www.sedar.com).Select financial highlights from the Financial Statements include the following:The Personas Social platform generated gross revenue of $2.88 million during the FY2020 while gross margin had improved to 40% from 24% in fiscal year ended February 28, 2019GAAP net loss decreased to $4.4 million in FY2020 from $24.3 million in fiscal year ended February 28, 2019.GAAP net loss per share was $0.016 for FY2020 as compared to $0.109 for fiscal year ended February 28, 2019.Shareholders...

Continue reading

Ceres Acquisition Corp. Reports Second Quarter 2020 Financial Results

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Ceres Acquisition Corp. (Neo: CERE.U and CERE.WT) (“Ceres” or the “Corporation”) is reporting its financial results as of June 30, 2020 and for the period from incorporation to June 30, 2020. The Corporation’s unaudited interim financial statements, along with the accompanying management’s discussion and analysis, have been filed on the System for Electronic Document Analysis and Retrieval (SEDAR) and may be viewed by interested parties under the Corporation’s profile at www.sedar.com.About Ceres Acquisition Corp.Ceres is a newly organized special purpose acquisition corporation incorporated under the laws of the Province of British Columbia for the purpose of effecting an acquisition of one or more businesses or assets, by way of a merger, amalgamation, arrangement, share exchange, asset...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.